Prelude Therapeutics (PRLD) Competitors $0.82 0.00 (-0.26%) Closing price 03:59 PM EasternExtended Trading$0.82 +0.00 (+0.37%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRLD vs. DRUG, GALT, IMAB, TLSA, DERM, CYBN, DMAC, NVCT, PBYI, and ACRSShould you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include Bright Minds Biosciences (DRUG), Galectin Therapeutics (GALT), I-Mab (IMAB), Tiziana Life Sciences (TLSA), Journey Medical (DERM), Cybin (CYBN), DiaMedica Therapeutics (DMAC), Nuvectis Pharma (NVCT), Puma Biotechnology (PBYI), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry. Prelude Therapeutics vs. Its Competitors Bright Minds Biosciences Galectin Therapeutics I-Mab Tiziana Life Sciences Journey Medical Cybin DiaMedica Therapeutics Nuvectis Pharma Puma Biotechnology Aclaris Therapeutics Bright Minds Biosciences (NASDAQ:DRUG) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership. Which has more risk & volatility, DRUG or PRLD? Bright Minds Biosciences has a beta of -6.01, meaning that its stock price is 701% less volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Does the media refer more to DRUG or PRLD? In the previous week, Bright Minds Biosciences and Bright Minds Biosciences both had 1 articles in the media. Bright Minds Biosciences' average media sentiment score of 1.90 beat Prelude Therapeutics' score of 1.89 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Overall Sentiment Bright Minds Biosciences Very Positive Prelude Therapeutics Very Positive Do analysts rate DRUG or PRLD? Bright Minds Biosciences currently has a consensus price target of $83.25, suggesting a potential upside of 223.08%. Prelude Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 446.12%. Given Prelude Therapeutics' higher probable upside, analysts clearly believe Prelude Therapeutics is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Prelude Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, DRUG or PRLD? Bright Minds Biosciences has higher earnings, but lower revenue than Prelude Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.36-71.58Prelude Therapeutics$7M6.65-$127.17M-$1.69-0.49 Is DRUG or PRLD more profitable? Bright Minds Biosciences' return on equity of -14.56% beat Prelude Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -14.56% -14.29% Prelude Therapeutics N/A -89.18%-69.26% Do insiders & institutionals hold more shares of DRUG or PRLD? 40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 63.9% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryBright Minds Biosciences beats Prelude Therapeutics on 8 of the 14 factors compared between the two stocks. Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRLD vs. The Competition Export to ExcelMetricPrelude TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.52M$2.44B$5.50B$9.40BDividend YieldN/A1.79%4.25%4.09%P/E Ratio-0.499.1928.1319.86Price / Sales6.65673.20424.9198.68Price / CashN/A160.6835.5357.53Price / Book0.344.728.235.71Net Income-$127.17M$30.99M$3.24B$257.80M7 Day Performance-7.11%0.96%0.66%1.12%1 Month Performance-11.16%10.05%8.07%11.30%1 Year Performance-86.72%-3.54%28.44%16.88% Prelude Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRLDPrelude Therapeutics3.7073 of 5 stars$0.82-0.3%$4.50+450.1%-86.8%$46.18M$7M-0.48120Positive NewsDRUGBright Minds Biosciences2.4323 of 5 stars$25.65+3.4%$83.25+224.6%+1,854.3%$180.68MN/A-71.25N/APositive NewsGALTGalectin Therapeutics2.2796 of 5 stars$2.85+13.5%$6.00+110.5%+13.1%$180.38MN/A-3.969IMABI-Mab2.859 of 5 stars$2.14+0.5%$6.00+180.4%+31.9%$174.75M$3.89M0.00380Gap DownTLSATiziana Life Sciences1.171 of 5 stars$1.48flatN/A+85.2%$172.94MN/A0.008DERMJourney Medical2.4345 of 5 stars$7.41+3.6%$9.50+28.2%+21.8%$172.65M$56.13M-19.0090High Trading VolumeCYBNCybin2.8283 of 5 stars$7.47-2.2%$85.00+1,037.9%N/A$171.99MN/A-1.7150News CoverageDMACDiaMedica Therapeutics1.1817 of 5 stars$4.01+10.5%$8.00+99.5%+17.4%$171.95MN/A-6.2720Positive NewsGap DownHigh Trading VolumeNVCTNuvectis Pharma3.3346 of 5 stars$8.22+4.3%$17.00+106.8%+18.4%$171.75MN/A-7.278Positive NewsPBYIPuma Biotechnology4.2268 of 5 stars$3.45+1.8%$7.00+102.9%-12.9%$171.22M$230.50M4.48200ACRSAclaris Therapeutics2.0236 of 5 stars$1.58+0.6%$8.71+451.5%+17.9%$171.08M$18.72M-1.14100 Related Companies and Tools Related Companies Bright Minds Biosciences Alternatives Galectin Therapeutics Alternatives I-Mab Alternatives Tiziana Life Sciences Alternatives Journey Medical Alternatives Cybin Alternatives DiaMedica Therapeutics Alternatives Nuvectis Pharma Alternatives Puma Biotechnology Alternatives Aclaris Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRLD) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
